BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17947476)

  • 1. Wwox and Ap2gamma expression levels predict tamoxifen response.
    Guler G; Iliopoulos D; Guler N; Himmetoglu C; Hayran M; Huebner K
    Clin Cancer Res; 2007 Oct; 13(20):6115-21. PubMed ID: 17947476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer.
    Guler G; Huebner K; Himmetoglu C; Jimenez RE; Costinean S; Volinia S; Pilarski RT; Hayran M; Shapiro CL
    Cancer; 2009 Feb; 115(4):899-908. PubMed ID: 19130459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Wwox with ErbB4 in breast cancer.
    Aqeilan RI; Donati V; Gaudio E; Nicoloso MS; Sundvall M; Korhonen A; Lundin J; Isola J; Sudol M; Joensuu H; Croce CM; Elenius K
    Cancer Res; 2007 Oct; 67(19):9330-6. PubMed ID: 17909041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
    Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
    Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WWOX--the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis.
    Płuciennik E; Kusińska R; Potemski P; Kubiak R; Kordek R; Bednarek AK
    Eur J Surg Oncol; 2006 Mar; 32(2):153-7. PubMed ID: 16360296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
    Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
    Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.
    Haugan Moi LL; Hauglid Flågeng M; Gandini S; Guerrieri-Gonzaga A; Bonanni B; Lazzeroni M; Gjerde J; Lien EA; DeCensi A; Mellgren G
    Clin Cancer Res; 2010 Apr; 16(7):2176-86. PubMed ID: 20332317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
    Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
    J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients.
    Göthlin Eremo A; Wegman P; Stål O; Nordenskjöld B; Fornander T; Wingren S
    Oncol Rep; 2013 Apr; 29(4):1467-74. PubMed ID: 23381945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
    Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
    Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
    Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
    J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
    Hopp TA; Weiss HL; Parra IS; Cui Y; Osborne CK; Fuqua SA
    Clin Cancer Res; 2004 Nov; 10(22):7490-9. PubMed ID: 15569979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WWOX expression in different histologic types and subtypes of non-small cell lung cancer.
    Donati V; Fontanini G; Dell'Omodarme M; Prati MC; Nuti S; Lucchi M; Mussi A; Fabbri M; Basolo F; Croce CM; Aqeilan RI
    Clin Cancer Res; 2007 Feb; 13(3):884-91. PubMed ID: 17289881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wwox suppresses prostate cancer cell growth through modulation of ErbB2-mediated androgen receptor signaling.
    Qin HR; Iliopoulos D; Nakamura T; Costinean S; Volinia S; Druck T; Sun J; Okumura H; Huebner K
    Mol Cancer Res; 2007 Sep; 5(9):957-65. PubMed ID: 17704139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tamoxifen on transcriptional level of transforming growth factor beta (TGF-beta) isoforms 1 and 2 in tumor tissue during primary treatment of patients with breast cancer.
    Brandt S; Kopp A; Grage B; Knabbe C
    Anticancer Res; 2003; 23(1A):223-9. PubMed ID: 12680217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.